BioSpace News Archive

Aprea Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 1,050,000 shares of its common stock at a public offering price of $5.25 per share.

Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that the Company’s management team will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference, which is taking place in Boston, MA from March 6 – 8, 2023.

Chinook Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022 and provided corporate updates.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended December 31, 2022.

STRATA Skin Sciences, Inc. announced that it had been notified by Nasdaq that Strata has regained compliance with the Nasdaq listing requirements regarding minimum bid price, Rule 5550.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2022 financial results and recent portfolio execution.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted the fourth and final module of its modular submission to the FDA for premarket approval of Motiva Implants® in the United States.

Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries, announces the appointment of Cary Sucoff, J.D. to the company’s Board of Directors.

Neuronetics, Inc. announced the granting of inducement awards to eight new non-executive employees.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2022.